Tokyo, Apr 24, 2006 (JCN) - Chugai Pharmaceutical has filed a new drug application (NDA) for bevacizumab, its proprietary anti-tumor agent, with the Ministry of Health, Labor and Welfare. The company is seeking approval to use the agent for treating advanced or recurrent colorectal cancer. Bevacizumab, which is a humanized anti-VEFG monoclonal antibody, is currently marketed in the US and Europe under the trade name of Avastin.
